Skip to main content
AAN.com
Views & Reviews
October 29, 2014

Dietary treatment in adults with refractory epilepsy
A review

November 18, 2014 issue
83 (21) 1978-1985

Abstract

We review adjunctive ketogenic diet (KD) and modified Atkins diet (MAD) treatment of refractory epilepsy in adults. Only a few studies have been published, all open-label. Because of the disparate, uncontrolled nature of the studies, we analyzed all studies individually, without a meta-analysis. Across all studies, 32% of KD-treated and 29% of MAD-treated patients achieved ≥50% seizure reduction, including 9% and 5%, respectively, of patients with >90% seizure frequency reduction. The effect persists long term, but, unlike in children, may not outlast treatment. The 3:1 and 4:1 [fat]:[carbohydrate + protein] ratio KD variants and MAD are similarly effective. The anticonvulsant effect occurs quickly with both diets, within days to weeks. Side effects of both diets are benign and similar. The most serious, hyperlipidemia, reverses with treatment discontinuation. The most common, weight loss, may be advantageous in patients with obesity. Potential barriers to large-scale use of both diets in adults include low rate of diet acceptance and high rates of diet discontinuation. The eligible screened/enrolled subject ratios ranged from 2.9 to 7.2. Fifty-one percent of KD-treated and 42% of MAD-treated patients stopped the diet before study completion. Refusal to participate was due to diet restrictiveness and complexity, which may be greater for KD than MAD. However, long-term adherence is low for both diets. Most patients eventually stop the diet because of culinary and social restrictions. For treatment of refractory status epilepticus, only 14 adult cases of KD treatment have been published, providing insufficient data to allow evaluation. In summary, KD and MAD treatment show modest efficacy, although in some patients the effect is remarkable. The diets are well-tolerated, but often discontinued because of their restrictiveness. In patients willing to try dietary treatment, the effect is seen quickly, giving patients the option whether to continue the treatment.

Get full access to this article

View all available purchase options and get full access to this article.

REFERENCES

1.
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78:1548–1554.
2.
Neal EG, Chaffe HM, Edwards N, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008;7:500–506.
3.
Sharma S, Sankhyan N, Gulati S, Agarwala A. Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial. Epilepsia 2013;54:481–486.
4.
Hartman AL, Vining EP. Clinical aspects of the ketogenic diet. Epilepsia 2007;48:31–42.
5.
Kossoff EH, Zupec-Kania BA, Amark PE, et al. Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group. Epilepsia 2009;50:304–317.
6.
Freeman JM, Vining EP, Pillas DJ, Pyzik PL, Casey JC, Kelly LM. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics 1998;102:1358–1363.
7.
Lefevre F, Aronson N. Ketogenic diet for the treatment of refractory epilepsy in children: a systematic review of efficacy. Pediatrics 2000;105:E46.
8.
Keene DL. A systematic review of the use of the ketogenic diet in childhood epilepsy. Pediatr Neurol 2006;35:1–5.
9.
Hartman AL, Gasior M, Vining EP, Rogawski MA. The neuropharmacology of the ketogenic diet. Pediatr Neurol 2007;36:281–292.
10.
Hemingway C, Freeman JM, Pillas DJ, Pyzik PL. The ketogenic diet: a 3- to 6-year follow-up of 150 children enrolled prospectively. Pediatrics 2001;108:898–905.
11.
Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 2007;48:1303–1307.
12.
Vining EP. Long-term health consequences of epilepsy diet treatments. Epilepsia 2008;49(suppl 8):27–29.
13.
Kang HC, Chung DE, Kim DW, Kim HD. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia 2004;45:1116–1123.
14.
Kwiterovich PO, Vining EP, Pyzik P, Skolasky R, Freeman JM. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 2003;290:912–920.
15.
Masino SA, Rho JM. In:, Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds. Jasper's Basic Mechanisms of the Epilepsies, 4th ed. Bethesda, MD: National Center for Biotechnology Information (US); 2012.
16.
Masino SA, Li T, Theofilas P, et al. A ketogenic diet suppresses seizures in mice through adenosine A1 receptors. J Clin Invest 2011;121:2679–2683.
17.
Ma W, Berg J, Yellen G. Ketogenic diet metabolites reduce firing in central neurons by opening KATP channels. J Neurosci 2007;27:3618–3643.
18.
Juge N, Gray JA, Omote H, et al. Metabolic control of vesicular glutamate transport and release. Neuron 2010;68:99–112.
19.
Wheless JW. History of the ketogenic diet. Epilepsia 2008;49(suppl 8):3–5.
20.
Barborka C. Epilepsy in adults: results of treatment by ketogenic diet in one hundred cases. Arch Neurol 1930; 6:904–914.
21.
Sirven J, Whedon B, Caplan D, et al. The ketogenic diet for intractable epilepsy in adults: preliminary results. Epilepsia 1999;40:1721–1726.
22.
Nei M, Ngo L, Sirven J, Sperling MR. Ketogenic diet in adolescents and adults with epilepsy. Seizure 2014;23:439–442.
23.
Mosek A, Natour H, Neufeld MY, Shiff Y, Vaisman N. Ketogenic diet treatment in adults with refractory epilepsy: a prospective pilot study. Seizure 2009;18:30–33.
24.
Klein P, Janousek J, Barber A, Weissberger R. Ketogenic diet treatment in adults with refractory epilepsy. Epilepsy Behav 2010;19:575–579.
25.
Lambrechts DA, Wielders LH, Aldenkamp AP, Kessels FG, de Kinderen RJ, Majoie MJ. The ketogenic diet as a treatment option in adults with chronic refractory epilepsy: efficacy and tolerability in clinical practice. Epilepsy Behav 2012;23:310–314.
26.
Atkins RC. Dr. Atkins' New Diet Revolution. New York: Harper Collins; 2002.
27.
Kossoff EH, McGrogan JR, Bluml RM, Pillas DJ, Rubenstein JE, Vining EP. A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy. Epilepsia 2006;47:421–424.
28.
Kossoff EH, Rowley H, Sinha SR, Vining EPG. A prospective study of the modified Atkins diet for intractable epilepsy in adults. Epilepsia 2008;49:316–319.
29.
Carrette E, Vonck K, de Herdt V, et al. A pilot trial with modified Atkins' diet in adult patients with refractory epilepsy. Clin Neurol Neurosurg 2008;110:797–803.
30.
Smith M, Politzer N, Macgarvie D, McAndrews MP, Del Campo M. Efficacy and tolerability of the modified Atkins diet in adults with pharmacoresistant epilepsy: a prospective observational study. Epilepsia 2011;52:775–780.
31.
Cervenka MC, Terao NN, Bosarge JL, et al. E-mail management of the modified Atkins diet for adults with epilepsy is feasible and effective. Epilepsia 2012;53:728–732.
32.
Kossoff EH, Henry BJ, Cervenka MC. Efficacy of dietary therapy for juvenile myoclonic epilepsy. Epilepsy Behav 2013;26:162–164.
33.
Kossoff EH, Nabbout R. Use of dietary therapy for status epilepticus. J Child Neurol 2013;28:1049–1051.
34.
Bodenant M, Moreau C, Sejourne C, et al. Interest of the ketogenic diet in a refractory status epilepticus in adults [in French]. Rev Neurol 2008;164:194–199.
35.
Wusthoff CJ, Kranick SM, Morley JF, Christina Bergqvist AG. The ketogenic diet in treatment of two adults with prolonged nonconvulsive status epilepticus. Epilepsia 2010;51:1083–1085.
36.
Nam SH, Lee BL, Lee CG, et al. The role of ketogenic diet in the treatment of refractory status epilepticus. Epilepsia 2011;52:e181–e184.
37.
Cervenka MC, Hartman AL, Venkatesan A, Geocadin RG, Kossoff EH. The ketogenic diet for medically and surgically refractory status epilepticus in the neurocritical care unit. Neurocrit Care 2011;15:519–524.
38.
Thakur KT, Probasco JC, Hocker SE, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology 2014;82:665–670.
39.
Baumeister FA, Oberhoffer R, Liebhaber GM, et al. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics 2004;35:250–252.
40.
Payne NE, Cross JH, Sander JW, Sisodiya SM. The ketogenic and related diets in adolescents and adults: a review. Epilepsia 2011;52:1941–1948.
41.
Gruenthal M. Comment: should we induce ketosis in super-refractory status epilepticus? Neurology 2014;82:669.

Information & Authors

Information

Published In

Neurology®
Volume 83Number 21November 18, 2014
Pages: 1978-1985
PubMed: 25355830

Publication History

Received: March 12, 2014
Accepted: August 20, 2014
Published online: October 29, 2014
Published in print: November 18, 2014

Permissions

Request permissions for this article.

Disclosure

P. Klein is on UCB Pharma, GlaxoSmithKline, and Eisai speakers' bureaus, has served on Advisory Boards of Acorda, Eisai, and Sunovion, and has participated in clinical trials sponsored by UCB Pharma, Eisai, GlaxoSmithKline, Sunovion, Lundbeck, and SK Life Sciences. I. Tyrlikova reports no disclosures relevant to the manuscript. G. Mathews has participated in clinical trials sponsored by UCB Pharma, Eisai, GlaxoSmithKline, Lundbeck, and SK Life Sciences. Go to Neurology.org for full disclosures.

Study Funding

No targeted funding reported.

Authors

Affiliations & Disclosures

Pavel Klein, MBBChir
From the Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD.
Disclosure
Scientific Advisory Boards:
1.
Accorda,Inc: advisory board Eisai: advisory board UC Davis: DSMB, UC Davis Allopregnanolone TBI Clinical Trial (no compensation received to-date)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Speaker's bureau: UCB Pharma, Inc; Glaxo Smith Kline, travel expenses related to speaking Cyberonics: travel to a company-sponsored meeting
Editorial Boards:
1.
NONE
Patents:
1.
U.S. Patent Application No. 62/024,827 �KETOGENIC FOOD COMPOSITIONS AND USES THEREOF� Applicant: OH! MBF Reference No.: 207953-9003-US00 Application No. 62/024,827 The application was filed on July 15, 2014 (after the submission of the final revision of the present manuscript).The patent application is for use of ketogenic foods for various madical conditions.
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Self-employed
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Speaker's bureau: UCB Pharma, Inc; Glaxo Smith Kline; Eisai; Sunovion
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ivana Tyrlikova, MD
From the Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
1) Mid-Atlantic Epilepsy and Sleep Center,Clinical Research Associate, 1.5 year
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Gregory C. Mathews, MD, PhD
From the Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence to Dr. Klein: [email protected]
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Pavel Klein: contributed to the writing of the manuscript. Ivana Tyrlikova: contributed to the writing of the manuscript. Gregory Mathews: contributed to the writing of the manuscript.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Keto Is Not Just for Kids: A Randomized Trial of a Modified Atkins Diet for Adolescents and Adults With Anti-Seizure Medication-Resistant Epilepsy, Epilepsy Currents, 23, 3, (147-149), (2023).https://doi.org/10.1177/15357597231157488
    Crossref
  2. Modifizierte Atkins Diät bei therapierefraktärer Epilepsie, Fortschritte der Neurologie · Psychiatrie, 91, 07/08, (279-279), (2023).https://doi.org/10.1055/a-2080-1365
    Crossref
  3. Difficulties in the implementation of the ketogenic diet in adult patients with refractory epilepsy, Epilepsy & Behavior, 144, (109234), (2023).https://doi.org/10.1016/j.yebeh.2023.109234
    Crossref
  4. Prospective study of the modified Atkins diet in adult drug-resistant epilepsy: effectiveness, tolerability, and adherence, Neurología (English Edition), (2023).https://doi.org/10.1016/j.nrleng.2021.10.008
    Crossref
  5. Brain trauma, ketogenic diets, and ketogenesis via enteral nutrition, Diet and Nutrition in Neurological Disorders, (257-280), (2023).https://doi.org/10.1016/B978-0-323-89834-8.00006-4
    Crossref
  6. Neurology, Ketogenic, (237-306), (2023).https://doi.org/10.1016/B978-0-12-821617-0.00006-1
    Crossref
  7. Exercise and Nutritional Guidelines for Weight Loss and Weight Maintenance in the Obese Female, The Active Female, (579-598), (2023).https://doi.org/10.1007/978-3-031-15485-0_32
    Crossref
  8. The Role of Ketogenic Diet in the Treatment of Neurological Diseases, Nutrients, 14, 23, (5003), (2022).https://doi.org/10.3390/nu14235003
    Crossref
  9. Influence of Aging, Macronutrient Composition and Time-Restricted Feeding on the Fischer344 x Brown Norway Rat Gut Microbiota, Nutrients, 14, 9, (1758), (2022).https://doi.org/10.3390/nu14091758
    Crossref
  10. Fats, Friends or Foes: Investigating the Role of Short- and Medium-Chain Fatty Acids in Alzheimer’s Disease, Biomedicines, 10, 11, (2778), (2022).https://doi.org/10.3390/biomedicines10112778
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share